Angeion Rolls Out Lyra 2020 ICD At ACC Following FDA Approval March 5
This article was originally published in The Gray Sheet
Executive Summary
FDA's March 5 sign-off on a premarket approval application supplement for Angeion's single-chamber Lyra 2020 implantable cardioverter defibrillator allowed for a timely launch of the product at the American College of Cardiology's 48th Annual Scientific Sessions, March 7-10 in New Orleans.